Table 2.
Episodes of grade 3 or 4 toxicities possibly attributable to lestaurtinib
| Dose level (mg/M2/dose) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 35 | 45 | 55 | 62.5 | 70 | 77.5 | 85 | 92.5 | 120 | |
| (# Subjects) | (3) | (3) | (3) | (7) | (5) | (10) | (4) | (3) | (3) | (6) |
| (# Total courses) | (7) | (7) | (9) | (11) | (9) | (40) | (61) | (5) | (28) | (27) |
| Toxicity | ||||||||||
| Neutropeniaa | 2b | 2b | ||||||||
| Hepatic (ALT) | 1 | 6c | 1 | |||||||
| Hepatic (AST) | 1 | 1 | ||||||||
| Metabolic/laboratory (Lipase) | 1 | 1 | ||||||||
| Metabolic/laboratory (Amylase) | 1d | 1d | 1 | |||||||
a
Subjects did not have bone marrow involvement at baseline
b
One patient at that dose level
c
6 episodes in 3 patients
d
2 episodes in 1 patient after dose reduction